Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial-Reference-Cited by-同舟云学术

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Published:2016-07 Issue:7 Volume:17 Page:883-895
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Antonia Scott J,López-Martin José A,Bendell Johanna,Ott Patrick A,Taylor Matthew,Eder Joseph Paul,Jäger Dirk,Pietanza M Catherine,Le Dung T,de Braud Filippo,Morse Michael A,Ascierto Paolo A,Horn Leora,Amin Asim,Pillai Rathi N,Evans Jeffry,Chau Ian,Bono Petri,Atmaca Akin,Sharma Padmanee,Harbison Christopher T,Lin Chen-Sheng,Christensen Olaf,Calvo Emiliano

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Small cell lung cancer: where do we go from here?;Byers;Cancer,2015

2. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer;Hanna;J Clin Oncol,2006

3. Treatment options for small cell lung cancer—do we have more choice?;Puglisi;Br J Cancer,2010

4. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease;Zatloukal;Ann Oncol,2010

5. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer;Schmittel;Ann Oncol,2011

Cited by 1102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer;Cell Discovery;2024-09-04

2. Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk;Blood Reviews;2024-09

3. Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study;Lung Cancer;2024-09

4. Challenges and future perspectives for the use of temozolomide in the treatment of SCLC;Cancer Treatment Reviews;2024-09

5. Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer;Cancer Research Communications;2024-09-01